Researchers inhibit tumor growth in new subtype of lung cancer
BOSTON – Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease.
A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC), instructor of medicine at Harvard Medical School and a member of the Harvard Stem Cell Institute, have identified a subtype of human adenocarcinoma. The research could help determine which individuals are at greatest risk of developing lung tumors that may be amenable to a new therapy to inhibit their progression. The results – done in collaboration with the Cancer Science Institute at the National University of Singapore (CSI NUS) – were published today in the journal Science Translational Medicine.
"Advances in lung cancer therapy require a greater understanding of the molecular origins of this deadly disease," said last corresponding author Levantini, who is also a researcher at the Institute of Biomedical Technologies at the Italian National Research Council (ITB-CNR). "Understanding the differences among lung cancers also could lead to innovations in treatment strategies and allow us to overcome drug-resistance, relapse and disease progression."
Levantini and colleagues previously showed that NSCLC tumor cells frequently express too little or none of a transcription factor called C/EBPα, a protein that regulates gene expression and cell proliferation in lung tissues. It's also known to play a role in a form of leukemia, as well as liver cancer, squamous cell skin carcinomas, squamous cell cancers of the head and neck and other cancers. In their previous work, the scientists suspected that C/EBPα may act as a tumor suppressant in normal cells, but the mechanism by which its absence promoted lung cancer tumors remained unclear.
In a series of in vitro experiments, the researchers demonstrated that C/EBPα indeed works as a tumor suppressant by restraining the expression of another molecule known to play a role in triggering and maintaining tumor growth. This molecule, called BMI1, is an oncogenic protein that has been implicated in colon cancer, a form of leukemia and breast and gastric cancers.
To determine the relationship between the suspected tumor suppressor (C/EBPα) and the oncogenic protein (BMI1), the researchers first altered a line of human adenocarcinoma cells to overexpress C/EBPα. That led to a marked reduction in the expression of BMI1. When the team analyzed tissues from 261 patients with NSCLC, they found an inverse correlation between the two molecules; that is, more than 80 percent of patient tissues with low levels of the tumor suppressing C/EBPα were positive for BMI1 expression. Likewise, an analysis tissue samples from patients with lung adenocarcinoma with no or low C/EBPα expression revealed that those with lower levels of BMI1 were more likely to survive, a pattern that has prognostic value, the researchers wrote.
"Our findings suggest that the lung cancer subtype defined by the loss of C/EBPα expression might specifically benefit from therapies that inhibit BMI1," the scientists wrote. "Thus, identifying factors that modulate its expression has generated major clinical interest."
The research team was also able to validate its findings in mice. In one set of experiments with mice engineered to express no C/EBPα, the scientists found an inverse relationship between the transcription factor and BMI1 that was nearly identical to its data from human adenocarcinoma. By manipulating BMI1 expression in vivo, the researchers were also able to confirm that decreasing the expression of the oncogenic protein was enough to fully inhibit tumor formation and even significantly arrest tumor growth.
"BMI1 plays a substantial role in many solid tumors, including one of the most aggressive models of lung cancer, and its expression is linked with tumor growth, invasion, metastasis, prognosis and recurrence," Levantini said. "Our findings could help us design better therapies for the subset of adenocarcinoma patients with low C/EBPα and high BMI1 expression pattern."
Study coauthors include first author Kol Jia Yong, Henry Yang, Bhavin M. Thakkar, Ross A Soo and co-corresponding author Daniel G. Tenen, all of the CSI NUS; BIDMC investigators Daniela S. Basseres, Robert S. Welner, Wen Cai Zhang, Meritxell Alberich-Jorda, Junyan Zhang, Lorena Lobo de Figueiredo-Pontes, Chiara Battelli, Christopher J. Hetherington, Min Ye, Hong Zhang, Karen O'Brien, Olivier Kocher, Pu Zhang and Bing Lim; Benedict Yan; Giorgia Maroni; Maria Cristina Magli; Alain C. Borczuk; Lyuba Varticovski; Young-Choon Moon; Nadiya Sydorenko; Liangxian Cao; and Thomas W. Davis; Atsushi Iwama; Balazs Halmos and Donna Neuberg. For a full list of contributors and their institutions, please see the full article online.
This work was funded by National Institutes of Health and National Cancer Institute (NIH/NCI P50 CA90578) Project 2 grant; the NCIS Yong Siew Yoon Research Grant through donations from the Yong Loo Lin Trust, the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research (STaR) Investigator Award, and by the National Research Foundation of Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative; FAMRI YCSA initiative; FAMRI YCSA 052409 and FAMRI CIA 103063, FAMRI YCSA 072165, Doctor's Cancer Foundation Award, IASLC Award, MIUR Flagship Interomics Project and MSMT Navrat grant LK21307. Researchers were supported by José Carreras fellowship, FIJC-10; NCI T32/K12/R25 award; the Agency for Science, Technology and Research (A*STAR), Singapore; the National Medical Research Council of Singapore (NMRC/CG/NCIS/2010) and the DF/HCC Cancer Center Support Grant 5P30 CA006516.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.bidmc.org.